Rigel Pharmaceuticals
RIGL
119 hedge funds and large institutions have $164M invested in Rigel Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 39 reducing their positions, and 32 closing their positions.
3,988% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $25K
9% more capital invested
Capital invested by funds: $150M → $164M (+$13.6M)
3% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 39
1.08% less ownership
Funds ownership: 7.4% → 6.32% (-1.1%)
14% less funds holding
Funds holding: 138 → 119 (-19)
59% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$12.4M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$1.34M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.25M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.24M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$525K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.05M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.58M |
| 3 |
Millennium Management
New York
|
-$3.68M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$3.03M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.58M |
RIGL Hedge Fund Activity: Q4 2022 in Review
119 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2022, worth a combined $164M — up 9% from $150M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of RIGL and 13 opened new positions — a net loss of 19 holders — while 39 trimmed existing stakes and 38 added.
The largest buyer was Armistice Capital, adding an estimated $12.4M. The largest seller was Fidelity Investments, cutting an estimated $6.05M.
- 119 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2022, down from 138 in Q3 2022.
- Funds reported $164M of Rigel Pharmaceuticals stock for Q4 2022, up 9% quarter-over-quarter.
- 13 funds opened new Rigel Pharmaceuticals positions in Q4 2022 and 32 closed out, a net change of -19 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2022 was Armistice Capital, an estimated $12.4M added.
- The largest Rigel Pharmaceuticals seller in Q4 2022 was Fidelity Investments, an estimated $6.05M sold.
Based on aggregated 13F filings for Q4 2022.